👁️ Could gene therapy reduce wet AMD injections? Two-year PRISM data show 66% of more recently diagnosed patients needed no supplemental injections after investigational 4D-150. 🎥 Veeral Sheth, MD, discusses the findings. ▶️ ow.ly/o58N50ZZlFr #AAO2026 #Retina

👁️ Does JIA-associated uveitis really end with childhood? For many patients, inflammation, treatment dependence and ocular complications can continue into adulthood. What should ophthalmologists know? 🔗 Read more: ow.ly/qcC950ZLQOt #Uveitis #Retina

👁️ Could gene therapy reduce the burden of DME injections? At #AAO2026, Arshad M. Khanani, MD, discusses promising early Phase 2 ELAAVATE findings with Diana V. Do, MD. 🎥 Watch: ow.ly/b5P850ZZloX #Retina #GeneTherapy

EyePoint announced plans to reduce its workforce by 53% and end its phase 3 nAMD trials early after Duravyu failed to meet the primary endpoint in the LUCIA trial. The company will shift its focus to ongoing phase 3 studies in DME. Read here: retinalphysician.com/news/20…

👁️ Can a single injection deliver lasting benefits in diabetic retinopathy? At #RetinaSociety2026, Nikolas London, MD, reviews 3-year ALTITUDE findings for investigational gene therapy sura-vec. 🎥 Watch: ow.ly/b0pW50ZWb6y

👁️ New Phase 3 VISTA results for investigational XLRP gene therapy laru-zova debuted at #AAO2026. 🎥 Robert A. Sisk, MD, discusses visual acuity findings, safety and next steps in an exclusive Retina Minute interview. ▶️ ow.ly/ucAu50ZXVA5 #Retina #GeneTherapy

👁️ LUGANO: 42% less treatment burden, but a missed primary endpoint. At #RetinaSociety2026, Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, discuss the phase 3 EYP-1901 findings in wet AMD. 🎥 Watch: ow.ly/3chi50ZWb3u #Retina #WetAMD

📍 Coverage from #RetinaSociety2026 👁️ Could epiretinal membrane removal reduce injection burden in wet AMD? In a small study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery. 🔗 Read more: ow.ly/OuZz50ZWbI6 #Retina

👁️ Stay current on the latest developments shaping retinal care. Subscribe to Retinal Physician for coverage of clinical trials, treatments, surgical techniques, and more. 📩 Sign up: ow.ly/gv0150ZTpqh #Ophthalmology #Retina

🔬 At #AAO2026, Charles C. Wykoff, MD, PhD, presented positive phase 3 DAYBREAK results for investigational nAMD therapies tarcocimab and tabirafusp. 54% of tarcocimab patients achieved 24-week dosing intervals. 🔗 Read more:ow.ly/4xVk50ZWQ4f #Retina #WetAMD

📍 We're in New Orleans! ⚜️ AAO 2026 is officially underway, and the Retinal Physician team is here for Retina Subspecialty Day! 👁️ We're excited to reconnect with the retina community, explore the latest developments in retinal care, and catch up with familiar faces! #AAO2026

👁️ Could optogenetics offer new hope for severe vision loss? Diana V. Do, MD, and Allen C. Ho, MD, discuss the FDA's acceptance of MCO-010's application, how the therapy works and what's next. 🎥 Watch: ow.ly/XxVf50ZW9Yo #Retina #Optogenetics

💉 When are eye drops no longer enough for noninfectious uveitis? Howard F. Fine, MD, explores when to escalate treatment and how injectable corticosteroids can help provide targeted, durable control. 💡 Read more: ow.ly/vF7y50ZLRIm #Uveitis #Retina

🎥 From #RetinaSociety2026 Kenneth C. Fan, MD, MBA, and Baruch D. Kuppermann, MD, PhD, join Diana V. Do, MD, to discuss findings from the TEASE program, safety and efficacy, and the ongoing phase 3 NORTHSTAR trial. ▶️ Watch the discussion: ow.ly/oCyb50ZTV9l

📋 “Suspicious lesion” or “possible melanoma”... how should you code it? Elizabeth Cifers, MBA, MSW, CHC, CPC, breaks down common ocular tumor coding challenges and documentation pitfalls. 🔎 Read the Coding Q&A: ow.ly/aQPu50ZLS8P #OcularOncology #MedicalCoding

🎥 From Retina Society 2026 Jeremy Wolfe, MD, MS, joins Diana V. Do, MD, to discuss sustained vision and fluid control, long-term safety, and refill intervals with the port delivery system. ▶️ Watch the discussion: ow.ly/flhl50ZTULM #RetinaSociety #Retina #nAMD

👁️ Phase 3 DAYBREAK has met its primary endpoint in wet AMD. Kodiak reports tarcocimab tedromer and tabirafusp-ted achieved noninferior vision gains vs aflibercept, with 54% of tarcocimab patients achieving 6-month durability. 🔗 ow.ly/yWqi50ZSYEk #WetAMD #Retina

What a few days at #RetinaSociety2026 in LA! 👁️🌴 The Retinal Physician team was there catching up with the retina community and covering the latest clinical trial data, emerging therapies, surgical research, and more. Catch up on all our coverage here: ow.ly/XStw50ZT5E8

💧 Could 30 seconds be enough before an intravitreal injection? A study found 0.05% aqueous chlorhexidine significantly reduced conjunctival bacteria after 30 seconds, with similar reductions at 60 and 90 seconds. 🔗 Read more: ow.ly/px6A50ZSYuc #Retina #Ophthalmology

👁️ Can radiation retinopathy be prevented before it threatens vision? Hannah Hongan Chen, MD, and Arun D. Singh, MD, explore strategies to reduce risk following plaque brachytherapy for choroidal melanoma. 🔗 Read more: ow.ly/X4ZX50ZLR9U #Retina #OcularOncology